Neurocrine Biosciences Inc (NBIX)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	341,300	385,900	339,200	369,700	249,700	191,000	176,400	64,000	154,500	58,200	12,200	71,400	89,600	444,800	364,700	402,000	407,300	93,400	204,800	176,500
Total stockholders’ equity	US$ in thousands	2,589,700	2,718,900	2,509,200	2,386,100	2,232,000	2,002,100	1,853,000	1,684,500	1,707,800	1,544,600	1,423,400	1,391,100	1,374,000	1,346,000	1,279,200	1,205,600	1,126,200	804,300	831,200	700,300
ROE		13.18%	14.19%	13.52%	15.49%	11.19%	9.54%	9.52%	3.80%	9.05%	3.77%	0.86%	5.13%	6.52%	33.05%	28.51%	33.34%	36.17%	11.61%	24.64%	25.20%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $341,300K ÷ $2,589,700K
= 13.18%

Neurocrine Biosciences Inc's return on equity (ROE) has displayed fluctuations over the period from March 31, 2020, to December 31, 2024.

The ROE started at a relatively high level of 25.20% in March 2020 and remained above 20% in the subsequent quarters until December 2020, where it peaked at 36.17%. This indicates that Neurocrine Biosciences was effectively utilizing its equity to generate profits during this period.

However, from March 2021 to June 2022, there was a declining trend in ROE, dropping to as low as 0.86% in June 2022. This significant decrease suggests a potential decrease in the company's profitability relative to its equity base during this period.

From September 2022 onwards, there was a gradual increase in ROE, reaching 14.19% by September 30, 2024. This uptrend indicates an improvement in the company's ability to generate profit from its shareholders' equity.

Overall, while there have been fluctuations in ROE over the analyzed period, it is essential for Neurocrine Biosciences to focus on maintaining a sustainable level of return on equity to ensure long-term profitability and shareholder value.